0000000000348748

AUTHOR

Maria-teresa Cedena

showing 5 related works from this author

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.

2020

[Purpose] Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by next-generation flow (NGF) cytometry. Thus, we aimed to determine the applicability and sensitivity of the flow MRD-negative criterion defined by the International Myeloma Working Group (IMWG).

OncologyMaleCancer Researchmedicine.medical_specialtyNeoplasm ResidualDiseaseResidualTHERAPYDexamethasoneFlow cytometryBortezomib03 medical and health sciences0302 clinical medicineInternal medicinehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansMeaning (existential)Longitudinal StudiesLenalidomideMultiple myeloma030304 developmental biologyCONSOLIDATIONRandomized Controlled Trials as Topic0303 health sciencesCOMPLETE RESPONSEmedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseaseFlow Cytometry3. Good healthClinical trialPROGNOSTIC VALUEbody regionsMRDOncologyClinical Trials Phase III as Topic030220 oncology & carcinogenesisFemaleSTEM-CELL TRANSPLANTbusinessMultiple MyelomaDARATUMUMABJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

2020

On behalf of the PETHEMA/GEM Cooperative Group.

MaleOncologyPhysics::Instrumentation and Detectorsmedicine.medical_treatmentKaplan-Meier EstimateHematopoietic stem cell transplantationBiochemistryhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsTumor MicroenvironmentProspective StudiesComputer Science::Operating SystemsIn Situ Hybridization FluorescenceMultiple myelomaRandomized Controlled Trials as TopicComputer Science::Cryptography and SecurityHazard ratioHematopoietic Stem Cell TransplantationHigh-Throughput Nucleotide SequencingHematologyMiddle AgedFlow CytometryPrognosisCombined Modality TherapyProgression-Free Survivalmedicine.anatomical_structureFemaleClonal HematopoiesisMultiple Myelomamedicine.medical_specialtyImmunologyTransplantation AutologousInternal medicinemedicineHumansClinical significanceProgression-free survivalComputer Science::Distributed Parallel and Cluster ComputingAgedAntineoplastic Combined Chemotherapy Protocolbusiness.industryCell Biologymedicine.diseaseTransplantationClinical Trials Phase III as TopicMyelodysplastic SyndromesMutationBone marrowbusinessMonoclonal gammopathy of undetermined significance
researchProduct

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

2021

PETHEMA/GEM Cooperative Group.

OncologyAdultBoron CompoundsMalemedicine.medical_specialtyNeoplasm ResidualPhysics::Instrumentation and DetectorsClinical Trials and ObservationsImmunologyPatient subgroupsGlycineDrug resistanceBiochemistryDexamethasoneBortezomibhemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineNeoplasmHumansProgression-free survivalTreatment resistanceLenalidomideComplete responseMultiple myelomaAgedChromosome AberrationsLymphoid Neoplasiabusiness.industryCell BiologyHematologyMiddle Agedmedicine.diseaseFlow CytometryProgression-Free Survivalbody regionsClinical trialTreatment OutcomeDrug Resistance NeoplasmFemalebusinessMultiple Myeloma
researchProduct

A machine learning model based on tumor and immune biomarkers to predict undetectable MRD and survival outcomes in multiple myeloma

2022

Abstract Purpose: Undetectable measurable residual disease (MRD) is a surrogate of prolonged survival in multiple myeloma. Thus, treatment individualization based on the probability of a patient achieving undetectable MRD with a singular regimen could represent a new concept toward personalized treatment, with fast assessment of its success. This has never been investigated; therefore, we sought to define a machine learning model to predict undetectable MRD at the onset of multiple myeloma. Experimental Design: This study included 487 newly diagnosed patients with multiple myeloma. The training (n = 152) and internal validation cohorts (n = 149) consisted of 301 transplant-eligible patients…

Machine LearningSurvival Ratemultiple myelomaCancer ResearchNeoplasm ResidualMRDOncologyimmunomonitoringHumansBiomarkersAgedmachine learning.
researchProduct

FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology

2022

Key Points FlowCT is a new computational workspace for unveiling cellular diversity and objectively identifying biomarkers in large immune monitoring studies.FlowCT identified T-cell biomarkers predictive of malignant transformation and survival in SMM and active MM data sets.

Smoldering Multiple MyelomaOncologymedicine.medical_specialtyImmunobiology and ImmunotherapyT cellMyeloma2423ImmunophenotypingImmune systemMaintenance therapyBone MarrowInternal medicineHumansMedicineBiomarker discoveryMultiple myelomaCancer immunologybusiness.industryHematologymedicine.diseaseFlow Cytometrymedicine.anatomical_structureSmouldering myelomaBone marrowbusinessBiomarkersmyeloma flow cytometry single cell smouldering myeloma
researchProduct